BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCDA BioCardia

Pre-Mkt 01-23 05:45:33 EST

1.31

+0.03

+2.34%

High1.37	Low1.28	Vol79.13K
Open1.28	D1 Closing1.28	Amplitude7.36%
Mkt Cap13.90M	Tradable Cap5.31M	Total Shares10.61M
T/O104.92K	T/O Rate1.95%	Tradable Shares4.05M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BCDA","market":"US","secType":"STK","nameCN":"BioCardia","latestPrice":1.31,"timestamp":1769115600000,"preClose":1.28,"halted":0,"volume":79133,"delay":0,"changeRate":0.02343750000000002,"floatShares":4052600,"shares":10612734,"eps":-1.65995,"marketStatus":"Pre-Mkt","change":0.03,"latestTime":"01-23 05:45:33 EST","open":1.28,"high":1.3742,"low":1.28,"amount":104917.4832,"amplitude":0.073594,"askPrice":1.49,"askSize":100,"bidPrice":1.18,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.65995,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769178600000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.31,"postHourTrading":{"tag":"盘后","latestPrice":1.29,"preClose":1.31,"latestTime":"18:45 EST","volume":521,"amount":672.9672,"timestamp":1769125519799,"change":-0.02,"changeRate":-0.015267,"amplitude":0.015267},"volumeRatio":1.1154347741771231,"impliedVol":0.046,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BCDA","defaultTab":"news","newsList":[{"id":"2605350054","title":"BioCardia CEO Peter Altman Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605350054","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605350054?lang=en_us&edition=fundamental","pubTime":"2026-01-22 06:03","pubTimestamp":1769033038,"startTime":"0","endTime":"0","summary":"Peter Altman, President and CEO of BioCardia Inc., reported a disposal of common shares of BioCardia Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 21, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL9Gn3VB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioCardia CEO Peter Altman Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2592941514","title":"BioCardia CEO Peter Altman Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592941514","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592941514?lang=en_us&edition=fundamental","pubTime":"2025-12-18 07:33","pubTimestamp":1766014395,"startTime":"0","endTime":"0","summary":"Peter Altman, President and CEO of BioCardia Inc., reported a disposal of common shares of BioCardia Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDLbjyPKy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BioCardia CEO Peter Altman Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2591825579","title":"BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2591825579","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591825579?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:00","pubTimestamp":1765890000,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., Dec.  16, 2025  (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/16/3206152/0/en/BioCardia-Cell-Therapy-for-Ischemic-Heart-Failure-to-Progress-to-Formal-Clinical-Consultation-with-Japan-PMDA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRGS","LU2500361329.USD","LU2637428348.USD","BK4157","BK4585","LU1894683264.USD","LU1894683348.USD","LU0738911758.USD","LU0949170772.SGD","LU1003077747.HKD","BK4097","BCDA","CMS","LU0553294199.USD","BK4208","BK4183","LU2346227817.USD","LU0661504455.SGD","LU2065732104.USD","BK4139","LU0545039389.USD","BK4588","MACE"],"gpt_icon":0},{"id":"2590156368","title":"BioCardia Inc. Files Initial Beneficial Ownership Statement for Director Marvin Slosman","url":"https://stock-news.laohu8.com/highlight/detail?id=2590156368","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590156368?lang=en_us&edition=fundamental","pubTime":"2025-12-11 10:48","pubTimestamp":1765421336,"startTime":"0","endTime":"0","summary":"BioCardia Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing lists Marvin Slosman as the beneficial owner in his capacity as a Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL2Dkhd8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BioCardia Inc. Files Initial Beneficial Ownership Statement for Director Marvin Slosman","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2588365049","title":"BRIEF-Biocardia Announces Election Of New Board Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2588365049","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588365049?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:04","pubTimestamp":1764767054,"startTime":"0","endTime":"0","summary":"BRIEF-Biocardia Announces Election Of New Board DirectorDec 3 (Reuters) - BioCardia Inc BCDA.O:BIOCARDIA ANNOUNCES ELECTION OF NEW BOARD DIRECTOR, MARVIN SLOSMAN AND COMPLETION OF TERM FOR OUTGOING DI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUA6NZWR2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2588467400","title":"BioCardia Appoints Marvin Slosman to Board as Richard Krasno Departs","url":"https://stock-news.laohu8.com/highlight/detail?id=2588467400","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588467400?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:01","pubTimestamp":1764766918,"startTime":"0","endTime":"0","summary":"BioCardia Inc. announced the election of Marvin Slosman to its Board of Directors, effective December 2, 2025. Richard Krasno has completed his term and departed the Board on the same date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL4GZc95:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2588404647","title":"Press Release: BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno","url":"https://stock-news.laohu8.com/highlight/detail?id=2588404647","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588404647?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:00","pubTimestamp":1764766800,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., Dec. 03, 2025  -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the election of Mr. Marvin Slosman to its Board of Directors, effective December 2, 2025. Dr. Richard Krasno, who has served on the Board since 2016, has completed his term and departed the Board effective December 2, 2025.\"We are very pleased to welcome Mr. Slosman to our Board,\" said Peter Altman, Chief Executive Officer of BioCardia. \"With deep expertise in the interventional cardiology sector and a strong track record in advancing breakthrough technologies from concept to commercialization, Mr. Slosman brings an exceptional understanding of regulatory pathways, global market expansion, and clinical value creation. He will be a tremendous asset as we continue to scale our portfolio and deliver innovative solutions for patients and providers.\". The Board and executive leadership team ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA","R","BK4099","03160","BK4604","BK4585","BK4555","BK4232","BK4588","TM","BK4022"],"gpt_icon":0},{"id":"2588577861","title":"BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2588577861","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588577861?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:30","pubTimestamp":1764595800,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., Dec.  01, 2025  (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA],a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3197000/0/en/BioCardia-to-Present-at-December-2025-CSI-Focus-Devices-in-Heart-Failure-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2586836491","title":"BioCardia Appoints New VP of Quality","url":"https://stock-news.laohu8.com/highlight/detail?id=2586836491","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586836491?lang=en_us&edition=fundamental","pubTime":"2025-11-25 01:03","pubTimestamp":1764003808,"startTime":"0","endTime":"0","summary":"BioCardia ( ($BCDA) ) just unveiled an update. On November 24, 2025, BioCardia, Inc. announced the appointment of Farhan Shahab as Vice President o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biocardia-appoints-new-vp-of-quality?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biocardia-appoints-new-vp-of-quality?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2585624174","title":"BioCardia Strengthens Leadership Team With the Addition of Farhan Shahab as Vice President of Quality","url":"https://stock-news.laohu8.com/highlight/detail?id=2585624174","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585624174?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:15","pubTimestamp":1763990100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUA97WYYP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2585261462","title":"Press Release: BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality","url":"https://stock-news.laohu8.com/highlight/detail?id=2585261462","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585261462?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:15","pubTimestamp":1763990100,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., Nov. 24, 2025  -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the appointment of Farhan Shahab as Vice President of Quality. Mr. Shahab brings over 25 years of experience to BioCardia in similar executive roles.Mr. Shahab joins BioCardia from Welldoc , where he served as Vice President of Quality and Regulatory. Prior to that, he served as Senior Director of Regulatory Affairs and Quality Assurance at Intuity Medical , and as Director of Quality Assurance and Regulatory Compliance at Moximed, , and as Senior Director, Quality Engineering at AngioScore . Before that, he served as Manager, Quality Engineering and Quality Systems at Medtronic, supporting the integration of two major acquisitions. Mr. Shahab earned his BS in Chemical Engineering at the University of Massachusetts and his MBA from the University of Phoenix. He is also a Regulatory Affa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4022","BK4585","BK4232","RAC","BK4588","R","BK4120","BK4139","BK4604","03160","BK4099","TM","BK4555","TISI"],"gpt_icon":0},{"id":"2584924651","title":"BioCardia, Inc. Q3 Net Income USD -1.483 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584924651","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584924651?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:28","pubTimestamp":1763573315,"startTime":"0","endTime":"0","summary":"Nov 12 (Reuters) - BioCardia, Inc. Q3 operating income USD -1.488 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 12-NOV-202521:41:00.897 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD1dC68z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2583546336","title":"BioCardia’s Earnings Call: Progress Amid Financial Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2583546336","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583546336?lang=en_us&edition=fundamental","pubTime":"2025-11-14 08:18","pubTimestamp":1763079502,"startTime":"0","endTime":"0","summary":"Biocardia (($BCDA)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call from BioCardia painted a p...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biocardias-earnings-call-progress-amid-financial-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biocardias-earnings-call-progress-amid-financial-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCDA","PRGS"],"gpt_icon":0},{"id":"2583308534","title":"BioCardia’s Q3 2025: Clinical Progress and Financial Stability","url":"https://stock-news.laohu8.com/highlight/detail?id=2583308534","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583308534?lang=en_us&edition=fundamental","pubTime":"2025-11-13 12:07","pubTimestamp":1763006873,"startTime":"0","endTime":"0","summary":"Biocardia ( ($BCDA) ) has released its Q3 earnings. Here is a breakdown of the information Biocardia presented to its investors. BioCardia, Inc., b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biocardias-q3-2025-clinical-progress-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biocardias-q3-2025-clinical-progress-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCDA","PRGS","BK4097","LU2065732104.USD","BK4139"],"gpt_icon":0},{"id":"2583738585","title":"Cellular therapy developer BioCardia's Q3 net loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2583738585","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583738585?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:49","pubTimestamp":1762984160,"startTime":"0","endTime":"0","summary":"Cellular therapy developer BioCardia's Q3 net loss narrowsOverviewBioCardia Q3 net loss decreases to $1.5 mln from $1.7 mln last yearCompany closed $6 mln financing to support CardiAMP cell therapy in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO170:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2583585146","title":"BRIEF-BioCardia, Inc. Q3 Net Income USD -1.483 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583585146","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583585146?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:41","pubTimestamp":1762983660,"startTime":"0","endTime":"0","summary":"BRIEF-BioCardia, Inc. Q3 Net Income USD -1.483 Million\n\n\nNov 12 (Reuters) - BioCardia, Inc. Q3 operating income USD -1.488 million.\n\nQ3 basic EPS USD -0.24","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX95C416:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2583858562","title":"BioCardia, Inc. Q3 Operating Income USD -1.488 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583858562","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583858562?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:40","pubTimestamp":1762983615,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX95C416:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2583585646","title":"BioCardia, Inc. Q3 Basic EPS USD -0.24","url":"https://stock-news.laohu8.com/highlight/detail?id=2583585646","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583585646?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:40","pubTimestamp":1762983615,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLX95C416:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2583586894","title":"BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583586894","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583586894?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:40","pubTimestamp":1762983600,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., Nov.  12, 2025  (GLOBE NEWSWIRE) -- BioCardia, Inc.[Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/12/3186852/0/en/BioCardia-Reports-Third-Quarter-2025-Business-Highlights-and-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HF","BK4139","BCDA"],"gpt_icon":0},{"id":"2583887345","title":"BioCardia reports Q3 net loss of $1.5 million on increased R&D expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2583887345","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583887345?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:14","pubTimestamp":1762982096,"startTime":"0","endTime":"0","summary":"BioCardia Inc. reported a net loss of $1.5 million for the third quarter of 2025, a decrease from $1.7 million in the same period of 2024, primarily due to lower compensation expenses. For the nine months ended September 2025, the net loss increased to $6.2 million from $5.7 million in the prior year, reflecting higher expenses related to the closeout of the CardiAMP HF Trial and the start of enrollment in the CardiAMP HF II Trial. Research and development expenses were $936,000 for the quarter and $3.8 million for the nine-month period, both higher than the previous year. Net cash used in operations for the quarter was $1.7 million, down from $2.6 million in 2024, and $4.9 million for the nine months, compared to $5.5 million last year. In September, BioCardia completed a $6.0 million financing, with net proceeds of $5.2 million. Key business developments included ongoing approvability discussions for CardiAMP cell therapy, a submission for approval of the Helix Transendocardial Deliv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL4gvM7m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biocardia.com","stockEarnings":[{"period":"1week","weight":-0.0643},{"period":"1month","weight":0.0315},{"period":"3month","weight":-0.0576},{"period":"6month","weight":-0.4426},{"period":"1year","weight":-0.3762},{"period":"ytd","weight":0.048}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0173},{"period":"6month","weight":0.0814},{"period":"1year","weight":0.1361},{"period":"ytd","weight":0.0104}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.074663},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.026705},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.016712},{"month":4,"riseRate":0.428571,"avgChangeRate":0.016522},{"month":5,"riseRate":0.375,"avgChangeRate":-0.084107},{"month":6,"riseRate":0.25,"avgChangeRate":-0.048165},{"month":7,"riseRate":0.5,"avgChangeRate":-0.016411},{"month":8,"riseRate":0.25,"avgChangeRate":-0.102769},{"month":9,"riseRate":0.375,"avgChangeRate":0.008782},{"month":10,"riseRate":0.375,"avgChangeRate":-0.049332},{"month":11,"riseRate":0.5,"avgChangeRate":0.042585},{"month":12,"riseRate":0.375,"avgChangeRate":-0.012187}],"exchange":"NASDAQ","name":"BioCardia","nameEN":"BioCardia"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioCardia,BCDA,BioCardia股票,BioCardia股票老虎,BioCardia股票老虎国际,BioCardia行情,BioCardia股票行情,BioCardia股价,BioCardia股市,BioCardia股票价格,BioCardia股票交易,BioCardia股票购买,BioCardia股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction